Similasan, 0.5% recall — Thea Pharma, Inc. (Class II)

Thea Pharma, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Similasan, 0.5% — a Class II recall, initiated 2026-04-23 and posted to the FDA enforcement report on 2026-05-06, under recall number D-0501-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.”. From the product description, the form is eye drops, the strengths given are 0.5% and 10 mL and the package is described as 0.33 Fl oz (10 mL). 1 National Drug Code number is printed in the record: 59262-700-11. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in MA, United States. The FDA files it under event ID 98792 together with 1 other recall number, all listed and linked below. Within that event this is the ndc 59262-700-11 and product named Similasan configuration; the sibling records differ on ndc and product named and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0501-2026
FDA event ID 98792 (2 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Thea Pharma, Inc.
Recall initiated 2026-04-23
Reported by FDA 2026-05-06
Report lag 13 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record MA, United States
Product description (source) Similasan, iVIZIA, Sterile Lubricant Eye Drops (Povidone 0.5%), 0.33 Fl oz (10 mL), Made in France, Distributed by: Thea Pharma Inc., Waltham, MA 02451, NDC 59262-700-11

Reason reported by FDA

Lack of Assurance of Sterility: This recall has been initiated due to CGMP deviations found by the FDA during an inspection of the manufacturer.

24 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 26-word product description above; each is a literal substring of it.

Product named Similasan
Form Eye Drops
Strength 0.5% · 10 mL
Package 0.33 Fl oz (10 mL)
NDC 59262-700-11
Stated origin France
Distributed by Thea Pharma Inc., Waltham

Which configuration this record is

2 recall numbers share event 98792. They differ on ndc and product named and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0501-2026) D-0500-2026
NDC 59262-700-11 82584-700-11
Product named Similasan iVIZIA

Shared across all 2 records under this event: strength 0.5% · 10 mL; package 0.33 Fl oz (10 mL); form Eye Drops; fda tier Class II; recalling firm Thea Pharma, Inc.; the same reason text; initiated 2026-04-23; reported 2026-05-06.

Event context: 2 recall numbers under event 98792

One enforcement action, 2 recall numbers: the FDA filed 1 further configuration of this action under event 98792. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
iVIZIA, 0.5%D-0500-2026Class II0.5% · Eye Drops82584-700-112026-05-06

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Systane, 10gD-0491-2026Alcon Research LLCClass II2026-05-06
GenTeal Tears, 10gD-0492-2026Alcon Research LLCClass II2026-05-06
Optase Dry Eye Intense Drops (Glycerin 0.2%)D-0499-2026Scope HealthClass II2026-05-06
Phenylephrine Hydrochloride Injectable Solution, 40mgD-0502-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate Injectable Solution, 1000 mcg/100 mLD-0503-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate injectable Solution in 0.9% Sodium ChlorideD-0504-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate Injectable Solution, 1250 mcg/25mLD-0505-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate Injectable Solution in 0.9% Sodium ChlorideD-0506-2026Wells Pharma OF Houston LLCClass II2026-05-06

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-05-06 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Ketamine Hydrochloride Injectable Solution, 50mg/mlD-0507-2026Wells Pharma OF Houston LLC50mg/ml · Solution2026-05-06
fentaNYL Citrate Injectable Solution in 0.9% Sodium ChlorideD-0508-2026Wells Pharma OF Houston LLC0.9% · Solution2026-05-06
Alendronate Sodium Oral Solution, 70 mg/75 mLD-0526-2026Hikma Pharmaceuticals Usa Inc70 mg/75 mL · Oral Solution2026-05-06
Furosemide Tablets, 80 mgD-0486-2026Leading Pharma, LLC80 mg · Tablets2026-04-29
FRESHKOTE LUBRICANT EYEDROPS, 10mLD-0489-2026Harrow Eye LLC10mL2026-04-29
Omega-3-Acid, 1 gramD-0493-2026The Harvard Drug Group LLC1 gram · Capsules2026-04-29
DEXTROSE INJECTION USP, 70%D-0496-2026B Braun Medical Inc70% · Injection2026-04-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 98792 returns all 2 of these recall numbers; a search on D-0501-2026 returns only this configuration. Match a package against 59262-700-11 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Thea Pharma, Inc. (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0501-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0501-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-06
Ingested
2026-08-22
Record hash
9cebfc338f670899

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.